CN104490884A - 治疗或预防炎症性皮肤疾病的化合物、制剂及方法 - Google Patents

治疗或预防炎症性皮肤疾病的化合物、制剂及方法 Download PDF

Info

Publication number
CN104490884A
CN104490884A CN201410590016.2A CN201410590016A CN104490884A CN 104490884 A CN104490884 A CN 104490884A CN 201410590016 A CN201410590016 A CN 201410590016A CN 104490884 A CN104490884 A CN 104490884A
Authority
CN
China
Prior art keywords
hydrogen
alkyl
pharmaceutically acceptable
independently
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410590016.2A
Other languages
English (en)
Chinese (zh)
Inventor
杰克·A·德约文
托马斯·M·罗西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Pharma SA
Sansrosa Pharmaceutical Development Inc
Original Assignee
Sansrosa Pharmaceutical Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/853,585 external-priority patent/US7439241B2/en
Application filed by Sansrosa Pharmaceutical Development Inc filed Critical Sansrosa Pharmaceutical Development Inc
Publication of CN104490884A publication Critical patent/CN104490884A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201410590016.2A 2004-05-25 2005-05-25 治疗或预防炎症性皮肤疾病的化合物、制剂及方法 Pending CN104490884A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57414204P 2004-05-25 2004-05-25
US60/574,142 2004-05-25
US10/853,585 2004-05-25
US10/853,585 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800223827A Division CN101426502A (zh) 2004-05-25 2005-05-25 治疗或预防炎症性皮肤疾病的化合物、制剂及方法

Publications (1)

Publication Number Publication Date
CN104490884A true CN104490884A (zh) 2015-04-08

Family

ID=35451386

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410590016.2A Pending CN104490884A (zh) 2004-05-25 2005-05-25 治疗或预防炎症性皮肤疾病的化合物、制剂及方法
CNA2005800223827A Pending CN101426502A (zh) 2004-05-25 2005-05-25 治疗或预防炎症性皮肤疾病的化合物、制剂及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2005800223827A Pending CN101426502A (zh) 2004-05-25 2005-05-25 治疗或预防炎症性皮肤疾病的化合物、制剂及方法

Country Status (15)

Country Link
EP (2) EP1761266B1 (enExample)
JP (2) JP4955543B2 (enExample)
KR (1) KR101257046B1 (enExample)
CN (2) CN104490884A (enExample)
AU (1) AU2005247467B2 (enExample)
BR (1) BRPI0511519A (enExample)
CA (2) CA2824612C (enExample)
DK (1) DK1761266T3 (enExample)
ES (2) ES2424644T3 (enExample)
MX (1) MXPA06013649A (enExample)
NZ (1) NZ552325A (enExample)
PL (1) PL1761266T3 (enExample)
PT (1) PT1761266E (enExample)
SI (1) SI1761266T1 (enExample)
WO (1) WO2005115395A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
MX2012004890A (es) * 2009-10-26 2012-09-28 Galderma Pharma Sa Metodos para tratar o prevenir eritema agudo.
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
WO2011117378A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
CN103298472A (zh) 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
ES2498217T5 (es) 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
RU2013123043A (ru) * 2010-10-21 2014-12-10 Галдерма С.А. Гелевая композиция для местного применения
CN101972272B (zh) * 2010-10-31 2012-07-04 无锡龙腾画材有限公司 一种二氧化氯皮肤凝胶及其制备方法
MX340859B (es) * 2010-11-16 2016-07-28 Allergan Inc Composiciones farmaceuticas que comprenden (3-(1-(1h-imidazol-4-il )etil)-2-metilfenil)metanol.
CA2827373C (en) * 2011-02-15 2019-05-14 Epi Health, Llc Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
WO2013057579A2 (en) * 2011-10-19 2013-04-25 Galderma Pharma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
CA2856507C (en) 2011-11-21 2017-03-21 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
EP2994120B1 (en) * 2013-05-06 2019-10-09 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
BR112016001677A2 (pt) * 2013-07-26 2017-09-19 Galderma Res & Dev Método para a redução ou inibição da progressão de um espessamento da pele em um indivíduo com essa necessidade e método para a regulação de uma resposta de egfr em um indivíduo com essa necessidade
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
KR101891185B1 (ko) 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
EP3319607A4 (en) * 2015-07-09 2019-04-03 Galderma S.A. METHOD FOR REDUCING HAIR LOSS IN CONNECTION WITH CHEMOTHERAPY
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
KR20190060007A (ko) 2016-10-31 2019-05-31 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
CN106727462B (zh) * 2016-11-14 2019-04-09 四川省人民医院 一种治疗面部皮炎的药物及其应用
US20220096467A1 (en) * 2019-01-12 2022-03-31 Cellix Bio Provate Limited Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof
US20220218590A1 (en) * 2019-05-14 2022-07-14 Abend Fritz Ventures Llc Compositions and methods for removal of skin adhesive patches, products, and residual adhesives
CA3190833A1 (en) * 2020-08-26 2022-03-03 Michael Mcdonald CROWLEY Compositions, devices and methods for treating nasal, otic and other tissue infection and/or inflammation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459157A (en) * 1991-11-27 1995-10-17 Zambon Group S.P.A. Pharmaceutical composition for ophthalmic use comprising a nonsteroidal anti-inflammatory and a decongestant drug
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
CN101897704A (zh) * 2000-07-14 2010-12-01 阿勒根公司 含有α-2肾上腺素能激动剂的组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4285967A (en) 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5910312A (en) * 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
JPH1129482A (ja) * 1997-05-14 1999-02-02 Taisho Pharmaceut Co Ltd 医薬組成物
ATE271048T1 (de) * 1997-11-24 2004-07-15 Procter & Gamble 5-(2-imidazolinylamino)-benzimidazol derivate, deren herstellung und deren verwendung als .alpha.-adrenoceptor agonisten mit verbesserter metabolischer stabilität
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
IN185228B (enExample) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
JP3520076B2 (ja) * 2001-10-02 2004-04-19 憲司 中村 皮膚外用剤
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459157A (en) * 1991-11-27 1995-10-17 Zambon Group S.P.A. Pharmaceutical composition for ophthalmic use comprising a nonsteroidal anti-inflammatory and a decongestant drug
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
CN101897704A (zh) * 2000-07-14 2010-12-01 阿勒根公司 含有α-2肾上腺素能激动剂的组合物

Also Published As

Publication number Publication date
KR101257046B1 (ko) 2013-04-22
PT1761266E (pt) 2013-06-04
JP2012072176A (ja) 2012-04-12
EP2481412A1 (en) 2012-08-01
EP2481412B1 (en) 2017-09-27
EP1761266A2 (en) 2007-03-14
SI1761266T1 (sl) 2013-08-30
DK1761266T3 (da) 2013-08-05
AU2005247467A1 (en) 2005-12-08
AU2005247467B2 (en) 2010-12-02
CA2567401A1 (en) 2005-12-08
ES2647618T3 (es) 2017-12-22
PL1761266T3 (pl) 2013-09-30
CA2824612C (en) 2016-08-16
CN101426502A (zh) 2009-05-06
NZ552325A (en) 2010-11-26
BRPI0511519A (pt) 2007-12-26
CA2824612A1 (en) 2005-12-08
WO2005115395A3 (en) 2009-04-09
JP5547705B2 (ja) 2014-07-16
JP2008500356A (ja) 2008-01-10
ES2424644T3 (es) 2013-10-07
CA2567401C (en) 2013-11-12
KR20070032716A (ko) 2007-03-22
EP1761266A4 (en) 2009-11-11
WO2005115395A2 (en) 2005-12-08
JP4955543B2 (ja) 2012-06-20
MXPA06013649A (es) 2007-07-09
EP1761266B1 (en) 2013-05-08

Similar Documents

Publication Publication Date Title
CN101816793B (zh) 用于治疗或预防酒渣鼻的化合物、制剂和方法
JP5547705B2 (ja) 紅斑を治療又は予防するための組成物
ES2463717T3 (es) Compuestos, formulaciones, y métodos para reducir las arrugas, pliegues y flacidez de la piel
EP3193907B1 (en) Method of treating prader-willi syndrome
ES2865118T3 (es) Composición farmacéutica que comprende (S)-(3-(1-(1H-imidazol-4-il)etil)-2-metilfenil)metanol para el tratamiento de neuropatía óptica
HK1174537A (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
HK1084591B (en) Compounds, formulations, and methods for treating or preventing rosacea

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150408

RJ01 Rejection of invention patent application after publication